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Abstract
Background: Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that
regulate lipid and glucose metabolism. PPARa is highly expressed in the liver and controls genes involved in lipid
catabolism. We previously reported that synthetic sphingolipid analogs, part of which contains shorter-length fatty
acid chains than natural sphingolipids, stimulated the transcriptional activities of PPARs. Sphingosine and
dihydrosphingosine (DHS) are abundant sphingoid bases, and ceramide and dihydroceramide are major ceramide
species in mammals. In contrast, phytosphingosine (PHS) and DHS are the main sphingoid bases in fungi. PHS and
phytoceramide exist in particular tissues such as the epidermis in mammals, and involvement of ceramide species
in PPARb activation in cultured keratinocytes has been reported. The purpose of the present study is to investigate
whether natural sphingolipids with C18 fatty acid and yeast-derived sphingoid bases activate PPARs as PPAR
agonists.
Method: Lipids of brewer’s yeast contain PHS- and DHS-based sphingolipids. To obtain the sphingoid bases, lipids
were extracted from brewer’s yeast and acid-hydrolyzed. The sphingoid base fraction was purified and quantified.
To assess the effects of sphingolipids on PPAR activation, luciferase reporter assay was carried out. NIH/3T3 and
human hepatoma (HepG2) cells were transfected with expression vectors for PPARs and retinoid × receptors, and
PPAR responsive element reporter vector. When indicated, the PPAR/Gal4 chimera system was performed to
enhance the credibility of experiments. Sphingolipids were added to the cells and the dual luciferase reporter assay
was performed to determine the transcriptional activity of PPARs.
Results: We observed that phytoceramide increased the transcriptional activities of PPARs significantly, whereas
ceramide and dihydroceramide did not change PPAR activities. Phytoceramide also increased transactivation of
PPAR/Gal4 chimera receptors. Yeast-derived sphingoid base fraction, which contained PHS and DHS, or authentic
PHS or DHS increased PPAR-dependent transcription. Additionally, phytoceramide stimulated PPARa activity in
HepG2 hepatocytes, suggesting that phytoceramide activates genes regulated by PPARa.
Conclusions: Phytoceramide and yeast-derived sphingoid bases activate PPARs, whereas ceramide and
dihydroceramide do not change the PPAR activity. The present findings suggest that phytoceramide acts as a
PPAR ligand that would regulate PPAR-targeted genes.
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Peroxisome proliferator-activated receptors (PPARs) are
members of nuclear hormone receptors that act as
ligand-activated transcription factors. PPARs regulate
expression of genes involved in lipid and glucose meta-
bolism [1,2]. PPARs consist of three isoforms, PPARa,
PPARb (also known as PPARδ), and PPARg. PPARa is
expressed at high levels in liver, where activated PPARa
promotes fatty acid oxidation and ketogenesis. PPARb is
expressed ubiquitously and is implicated in lipid catabo-
lism and energy production in adipose tissue and skele-
tal muscle [3]. PPARb is also involved in epithelial cell
differentiation and wound healing in the epidermis [4].
PPARg is highly expressed in white adipocytes where it
stimulates the intake of fatty acids and glucose and the
synthesis of triglycerides [5].
We previously reported that synthetic sphingolipid ana-
logs activated PPARs when assessed using the luciferase
reporter system [6]. This observation gave rise to the spec-
ulation that natural sphingolipids may act as PPAR
ligands. Ceramide is the basic structure of complex sphin-
golipids, which are present in the plasma membrane. It is
composed of a long-chain sphingoid base with the
2-amino group amide-linked to a fatty acid [7,8]. The fatty
acids are commonly saturated or mono-unsaturated, and
their chain length varies from 14 to 26. In mammalian
cells, sphingolipids contain a sphingoid base, mainly sphin-
gosine (Sph) or dihydrosphingosine (DHS). The major
type of sphingoid base, Sph, has a double bond between
C4 and C5 position, whereas DHS is saturated at that site
(Figure 1). Phytosphingosine (PHS), which has hydroxyl
group at the C4 position, exists in certain tissues, in parti-
cular the intestine, kidney and epidermis of mammals
[9-11]. All sphingolipid analogs that activated PPARs [5]
had a PHS-based structure. In the mammalian epidermis,
sphingolipids play a critical role in water retention and in
creating the permeability barrier against extraneous sub-
stances [11,12]. Expression of DES2, a hydroxylase enzyme
that produces phytoceramide from dihydroceramide, is
upregulated during the differentiation of cultured kerati-
nocytes [13]. It has been reported that PPARb expression
and activation brought about keratinocyte differentiation
in response to inflammatory signals, such as tumor necro-
sis factor-a and interferon-g, and that exogenous adminis-
tration of short-chain ceramides enhanced PPARb activity,
which increased the cells’ resistance to apoptosis [14].
These previous studies suggest that ceramide species are
responsible for PPARb activation during keratinocyte
differentiation.
In contrast to mammals, yeasts contain mainly two
sphingoid bases: PHS and DHS. Brewer’s yeast is a
member of budding yeasts, and residues of brewer’s
yeast after beer manufacturing contain sphingolipids
including mainly mannosyl-diinositolphosphoryl-
ceramide [M(IP)2C] [15,16].
Sphingolipids are found in many foodstuffs [17,18],
but the effect of dietary sphingolipids on PPAR activity
is not understood. In this study, we examine whether
ceramide species with C18 fatty acid, which is present in
mammals, act as PPAR ligands, using the luciferase
reporter assay system. We also extracted sphingoid
bases from brewer’s yeast residues and assessed their
effect on PPAR activity.
Materials and methods
Materials
C18 phytoceramide, C18 ceramide, C18 dihydroceramide,
C2 ceramide, PHS and DHS were purchased from Avanti
polar lipids (Alabaster, AL, USA). WY-14643 (WY), L-165,
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Figure 1 Chemical structure of ceramide species (ceramide,
phytoceramide and dihydroceramide).
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Sigma-Aldrich (St. Louis, MO, USA). C18 phytoceramide,
C18 ceramide and C18 dihydroceramide were dissolved in
chloroform/methanol (2:1 [vol:vol]), and then were dried
under reduced pressure using a Speed Vac concentrator.
The dried samples were dissolved in DMSO, and used in
treatment of the cells. The sphingoid bases were dissolved
in EtOH and were employed for cell treatment except as
indicated in the figure legends.
Preparation of sphingoid bases from brewer’s yeast
Lipids were extracted from brewer’s yeast, and saponi-
fied with 1 N NaOH in MeOH. The lipids were acid-
hydrolyzed with 9.4% H2O, 27.3% MeOH, 54.7% tetrahy-
drofuran, and 1 N HCl for 18 h at 60°C. After hydroly-
sis, an equal volume of hexane was added, then the
samples were centrifuged and the hexane phase was
removed. Partitioning was repeated another two times.
To one volume of sample half volume of 2 N NaOH
and equal volume of chloroform were added, and the
mixture was centrifuged for separation. The lower
chloroform phase was collected and washed twice with
Folch’s upper phase solution, and the chloroform phase
was dried by evaporation. Dried samples were dissolved
in 0.1 N NaOH and MeOH, 4:3 v/v, and sonicated in a
sonication bath, and an equal volume of chloroform was
added for partition. The upper aqueous phase was
removed and the lower chloroform phase was washed
twice by addition of an equal amount of Folch’su p p e r
phase. The washed lower phase was dried, and desalted
using Sep-pak Plus C18 cartridge (Waters, Milford, MA,
USA), and then the eluted sphingoid bases were used
for cell treatments. A small portion of samples were
used for high performance liquid chromatography
(HPLC) analysis. Samples were dissolved in 120 μlo f
EtOH and heated for 15 min at 60°C, then mixed with
15 μl of OPA reagent (1 mg/ml o-phthalaldehyde, 0.2%
v/v 2-mercaptoethanol in 3%, w/v, boric acid solution
adjusted to pH 10.5) and incubated at 60°C for 1 h.
After centrifugation at 10,000 g for 5 min, the superna-
tants were resolved by HPLC (Shimazu LC-10AD series;
Shimazu, Kyoto, Japan) on a pre-packed C18 reversed-
phase column (Cosmosil 5C18-AR-II; Nacalai Tesque,
Kyoto, Japan) using an isocratic eluent composition of
acetonitrile/distilled water (85:15, v/v) and a flow rate of
1 ml/min. The OPA derivatives were monitored at an
excitation wavelength of 340 nm and an emission wave-
length of 455 nm.
Luciferase reporter assay
NIH/3T3 and HepG2 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Sigma-Aldrich) con-
taining 2 mM L-glutamine and 25 mM glucose supple-
mented with 10% (v/v) heat-inactivated fetal calf serum
(Invitrogen, Carlsbad, CA, USA) and antibiotics (100
units/ml penicillin and 0.1 mg/ml streptomycin) (Sigma-
Aldrich) at 37°C in a humidified atmosphere of 5%
CO2-95% air. For luciferase measurement, cells were
plated in 96-well plates (BD Biosciences, Bedford, MA,
USA) at 1 × 10
4 cells and allowed to adhere for 24 h.
Cells were transfected using Lipofectamine 2000 (Invi-
trogen) at a ratio of 2.5 μl: 1 μg DNA, according to the
manufacturer’s instructions. Each well contained 10 ng
of full-length mouse PPAR (pCMX-PPARa,P P A R b,o r
PPARg), 10 ng of pCMX-RXR (retinoid × receptor), 160
ng of 4 × PPRE (PPAR responsive element) reporter
plasmid (a reporter plasmid) and 20 ng of pGL4 TK
Renilla luciferase plasmid (an internal control for nor-
malizing transfection efficiency). For luciferase assay
using the Gal4/PPAR chimera system, 150 ng of pG5
luc vector that contained Gal4 upstream activating
sequences (UAS), and 50 ng of pBIND mouse PPARa,
PPARb or PPARg (an expression plasmid for fusion pro-
tein of Gal4 DNA-binding domain and PPAR ligand
binding domain (LBD)) were transfected into NIH/3T3
cells. For AP-1 activity measurement, 180 ng of 6 × AP-
1 reporter plasmid and 20 ng of pGL4 TK Renilla luci-
ferase plasmid were transfected to NIH/3T3 cells.
Twenty-four hours after transfection, test compounds
were diluted with phenol red-free DMEM (Invitrogen)
containing 10% (v/v) charcoal-stripped fetal calf serum
(cFCS) and were added to each well. After 24 h, the
cells were lysed and assayed using a Dual-Glo Luciferase
Assay System (Promega, Madison, WI, USA) according
to the manufacturer’s protocol.
Cell viability analysis
NIH/3T3 cells were plated in a 96-well plate at a density
of 1 × 10
4 cells per well. Cells were treated with phenol
red-free DMEM (with 10% cFCS) containing indicated
compounds. Cell viability was assessed at 24 h post-
treatment using cell counting kit-8 (Dojin Chemical,
Kumamoto, Japan), following the manufacturer’s
protocol.
Statistical Analysis
Data are presented as means ± standard deviation (S.D.)
of three samples. Statistical analysis was performed
using an unpaired Student’st - t e s to ro n ew a yA N O V A
followed by Dunnett’s test. Statistical significance was
established at P < 0.05, 0.01 or 0.001 versus vehicle con-
trol. Each experiment was performed at least three
times and produced consistent results.
Results
Phytoceramide activates PPARs
The sphingolipid analogs that activated PPARs had a PHS-
based structure and a part of them had shorter-length fatty
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tested whether phytoceramide with C18 fatty acid, which
exists in mammalian cells, activates PPARs. Phytoceramide
at 10 μM significantly increased PPAR activity in NIH/3T3
cells (Figure 2A). PPARa and PPARg activities induced by
10 μM phytoceramide were increased by 1.5-fold and 1.2-
fold, respectively. PPARb was more intensely activated in
the presence of 10 μM phytoceramide (2.5-fold) than
PPARa and PPARg. WY, LD and CIG, which are synthetic
PPARa, PPARb and PPARg ligands, respectively, are used
as positive control reagents. In contrast, C18 ceramide did
not show significant PPAR activation. In the control
experiments for evaluating the specificity of PPAR activa-
tion, the luciferase activity of the pGL4.23 empty vector
that did not contain the PPRE sequence was not changed
by phytoceramide treatment in PPARa- and PPARg-trans-
fected cells (Figure 2B). In PPARb-transfected cells, LD
and 10 μM phytoceramide treatment decreased luciferase
activity of the empty reporter, probably owing to
decreased background transcription of luciferase. Taken
together, these results indicate that phytoceramide acti-
vates PPARs in a PPRE-dependent manner, but ceramide
does not change the activities.
To confirm the accuracy of the PPAR activation by
addition of phytoceramide, we employed another repor-
ter system in which the LBD of PPARs was fused to a
DNA-binding domain of the yeast transcription factor
Gal4 [19]. The chimera receptor can bind to Gal4 UAS
and activate transcription when ligands bind to PPAR
LBD. This method is independent of endogenous PPARs
and specific for ligand binding to PPARs [20]. Figure 3
shows that the transcriptional activation by exposure to
phytoceramide at 10 μMd e p e n d so nt h ep r e s e n c eo f
PPAR LBD. At this concentration, the activities of
PPARa,P P A R b and PPARg induced by phytoceramide
increase about 1.1-, 1.2- and 1.1-fold, respectively,
whereas that of the pBIND parental vector alone (Gal4
only) was not changed. In this assay system, the degree
of activation of PPARb was higher than that of PPARa
and PPARg, similarly to native PPARs (Figure 2A).
All these results obtained from different reporter
systems indicate that phytoceramide activates PPARs,
especially PPARb, suggesting that not only synthetic
sphingolipid analogs but also phytoceramide acts as an
agonist of PPARs.
Effect of yeast-derived sphingoid bases in PPAR activity
Ceramides are degraded to a sphingoid base and a fatty
acid by ceramidase. Thus, the possibility arose that PPAR
activation by phytoceramide might be caused by PHS
generated from phytoceramide. As shown in Figure 4,
10 μM PHS induced a 1.2-, 1.4- and 1.3-fold activation of
PPARa,P P A R b and PPARg, respectively, while 10 μM
phytoceramide caused a 1.3-, 1.6- and 1.6-fold activation
of PPARa,P P A R b and PPARg, respectively, indicating
that PHS also activated PPARs. Since yeast sphingolipids
have a PHS-based ceramide backbone, we next investi-
gated the effect of sphingolipids obtained from brewer’s
yeast on PPAR activation. M(IP)2C has a hydrophilic
head group moiety. Thus, the cells will be hard to uptake
and utilize it. To remove the hydrophilic head group
moiety, we hydrolyzed the lipids from yeast extracts, pur-
ified them and obtained a sphingoid base fraction. The
purified sphingoid base fraction was analyzed by HPLC.
Peaks corresponding to PHS and DHS were observed
at 1.03% and 2.84% of the extracted lipid, respectively
(Figure 5A and 5B). Original amounts of M(IP)2Cw i t h
PHS or DHS before acid hydrolysis were estimated from
this measurement. The sphingoid bases were added to
NIH/3T3 cells at the concentration of 1 μMP H Sa n d2 . 7
μM DHS (low concentration) or 5 μMP H Sa n d1 4μM
DHS (high concentration), in comparison with the same
concentrations of authentic PHS and DHS (Figure 5C).
Yeast-extracted sphingoid bases increased PPAR activities,
and the mixtures of authentic PHS and DHS raised the
activities of PPARs comparably to the equivalent concen-
trations of yeast-derived sphingoid bases. Intriguingly, the
activities of PPARs were stimulated by DHS alone as well
as PHS alone. We then examined the effect of dihydro-
ceramide, which was composed of DHS with a fatty acid.
In NIH/3T3 cells dihydroceramide did not show any
effect on transactivation of PPARs under the same condi-
tions as phytoceramide treatment (Figure 5D). These
results indicate that yeast-derived sphingoid bases can
activate PPARs, and that either PHS and/or DHS simi-
larly stimulate transcriptional activities of PPARs but
dihydroceramide does not alter PPAR activities. It was
considered that the PHS and/or DHS were responsible
for PPAR activation by yeast-derived sphingoid bases.
Activation of PPARs is not caused by alteration
of cell viability
It has been reported that exogenous administration of
ceramide exhibited a cytotoxic effect [21,22], and that
ceramide-generated endogenous ligand of PPARb
increased its activity via AP-1 pathway in keratinocytes
[14]. To investigate the possibility that the increased
luciferase activities by sphingolipid treatment could be
due to the secondary cytotoxic effect, cell viabilities in
the presence of sphingolipids were tested. C2 ceramide,
which was reported as an apoptotic inducer, exhibited
no alteration in the viability of NIH/3T3 cells in our
experiment (Figure 6A). Similarly, cell viability was not
changed by the addition of phytoceramide, ceramide,
dihydroceramide or the yeast-derived sphingoid bases,
PHS and DHS. In addition, phytoceramide did not
change the AP-1 activity in NIH/3T3 cells (Figure 6B).
These results suggest that PPAR activation by
Murakami et al. Lipids in Health and Disease 2011, 10:150
http://www.lipidworld.com/content/10/1/150
Page 4 of 11(A)
PPRE reporter Luciferase PPRE PPRE PPRE PPRE
P
P
A
R
R
X
R
0
0.5
1
1.5
2
Ctl WY 1   10
0
1
2
3
4
5
6
7
1   10
phytoceramide ceramide
Ctl LD 1   10 1   10
phytoceramide ceramide
(PM)
(PM)
PPARD
PPARE
** ***
**
***
0
0.5
1
1.5
2
2.5
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
Ctl CIG 1   10 1   10
phytoceramide ceramide
(PM)
PPARJ
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
***
**
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
Ctl WY 1 PM
phytoceramide
10 PM
phytoceramide
0
0.5
1
1.5
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y PPARD
0
0.5
1
1.5
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y PPARE
Ctl LD 1 PM
phytoceramide
10 PM
phytoceramide
0
0.5
1
1.5
R
e
l
a
t
i
v
e
 
l
u
c
i
f
e
r
a
s
e
 
a
c
t
i
v
i
t
y
***
Ctl CIG 1 PM
phytoceramide
10 PM
phytoceramide
PPARJ
Luciferase Empty reporter
(B)
P
P
A
R
R
X
R
*
Figure 2 Effects of phytoceramide on PPAR transcriptional activity. (A) NIH/3T3 cells were transfected with 4 × PPRE firefly luciferase
reporter plasmid along with expression plasmids for PPARs (PPARa, PPARb or PPARg) and RXR and an internal control TK Renilla luciferase
vector. After 24 h cultivation, the cells were treated with the indicated concentration of phytoceramide or ceramide for 24 h. As positive control,
10 μM of WY-14643 (WY), L-165,041 (LD) or ciglitazone (CIG) were used. (B) NIH/3T3 cells were transfected as described above, expect for an
empty luciferase reporter instead of 4 × PPRE firefly luciferase reporter. Twenty-four hours after transfection, phytoceramide was added to the
cells for 24 h. The luciferase activity of the cell was measured, and firefly luciferase activity was normalized to Renilla luciferase activity. The
activity of a vehicle control was expressed as 1 and the relative luciferase activities were presented as a fold induction to that of the vehicle
control. All results are shown as means ± S.D. (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, significantly different from the level of vehicle control
(Dunnett’s test).
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viability and AP-1 activation.
Phytoceramide activates PPARa in hepatocytes
PPARa is highly expressed in the liver where it has been
shown to promote fatty acid oxidation. Fibrate drugs
function as agonists of PPARa and have been used for
the treatment of hypertriglyceridemia [23]. To elucidate
whether phytoceramide induces PPARa activation in
hepatocytes, human hepatoma cells, HepG2, were used
instead of NIH/3T3 (Figure 7). Phytoceramide at 10 μM
caused a 1.1-fold induction of PPARa activity. This
result suggests that phytoceramide that was derived
from daily diets and reached the liver could stimulate
PPARa and regulate PPARa target genes in the liver.
Discussion
In the present study, we found that phytoceramide acti-
vated PPARs and that PPARb w a sm o r eh i g h l ys t i m u -
lated than PPARa and PPARg. However, ceramide and
dihydroceramide did not activate PPARs (Figure 2A and
5D). Analysis of the X-ray structure indicated a
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Figure 3 Effect of phytoceramide on PPAR activity in the Gal4/PPAR chimera system. The expression vector for PPAR LBD/Gal4 DBD and
Gal4 UAS luciferase reporter were transfected into NIH/3T3 cells. After 24 h, cells were treated with phytoceramide at the indicated
concentrations. The luciferase assay was performed as described in the legend to Figure 2A. All results are shown as means ± S.D. (n = 3). *P <
0.05, ***P < 0.001, significantly different from the level of vehicle control.
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human PPARg LBD [24,25]. The hydroxyl group at C4
position in phytoceramide is not present in ceramide
and dihydroceramide; therefore, the hydroxyl group at
C4 position might be involved in the transcriptional
activation of PPARs. Another hypothesis that could
explain the superiority of phytoceramide in PPAR acti-
vation is that phytoceramide is more easily taken up
into the cells than dihydroceramide and ceramide.
In that case, the structural difference among ceramide
species might have no correlation with PPAR activation.
Phytoceramide is synthesized mainly in the kidney,
intestine and skin in mammals, while PHS and DHS are
the major sphingoid bases in fungi. Fermented foods
contain the PHS-based sphingolipids derived from fungi,
and a some of the sphingolipids are hydrolyzed to
sphingoid bases in the small intestine [26]. The sphin-
goid bases are taken up by intestinal cells and reincor-
porated into complex sphingolipids such as ceramide
and sphingomyelin. Some of them reach the lymph,
blood and liver [26,27]. We observed that PHS con-
tained in food was absorbed and reached the mouse
liver (unpublished data). We also observed that phyto-
ceramide induced activation of PPARa in HepG2 hepa-
tocytes (Figure 7). Therefore, phytoceramide originating
from dietary yeast sphingolipids could be incorporated
to the cells, such as hepatocytes and adipocytes, and
activate PPARs, regulating the expression of PPARa
target genes.
In addition to phytoceramide, yeast-derived sphingoid
bases and authentic PHS and DHS treatment activated
PPARs (Figure 5C), while ceramide and dihydrocera-
mide treatment did not activate PPARs. There were no
distinct differences between yeast-derived sphingoid
bases and authentic sphingoid bases in PPAR activation,
but their effects were smaller than for the positive con-
trols (WY, LD and CIG) (Figure 5C). These results indi-
cate that activation of PPARs by yeast-derived sphingoid
bases does not reach maximal levels, suggesting that
unidentified factors included in yeast-derived sphingoid
bases do not contribute to PPAR activation. There is a
possibility that PHS and DHS interact directly with
PPARs and activate PPARs. The incorporation rate of
sphingoid bases into the cells is higher than that of cera-
mide species [28,29]. If PHS was a true ligand of PPARs,
PPAR activation occurring by PHS treatment would be
higher than phytoceramide treatment. However, the
activation of PPARs by PHS was not more potent than
phytoceramide at the same concentration, as shown in
Figure 4. Therefore, we considered that PHS-induced
activation of PPARs was caused by phytoceramide gen-
erated from PHS in the cells. It remains unclear why
DHS treatment activates PPARs or whether metabolites
of DHS are the active agents. Future studies are needed
to elucidate this question.
In this study, PPARb was most intensively stimulated
by phytoceramide in three PPARs. It has been reported
that liver-specific PPARb overexpression decreases glu-
cose production and increases glucose disposal in the
liver [30]. Moreover, transgenic mice overexpressing
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Figure 4 Comparison between phytoceramide and PHS in
PPAR activation. NIH/3T3 cells were transfected as described for
Figure 2A. PHS was dissolved in DMSO to carry out the experiments
under the same condition with phytoceramide. Transfected cells
were treated with phytoceramide or PHS at the indicated
concentrations for 24 h, and then the luciferase activity was
quantified. All results are shown as means ± S.D. (n = 3). *P < 0.05,
**P < 0.01, ***P < 0.001, significantly different from the level of
vehicle control.
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Figure 5 Effects of sphingoid bases derived from brewer’s yeast in PPAR activation. (A and B) Sphingoid base fraction from brewer’s yeast
was extracted, treated with o-phthalaldehyde, and analyzed by reversed-phase HPLC. The areas of PHS and DHS were quantified. (C) NIH/3T3
cells were transfected as described for Figure 2A. Cells were stimulated with the indicated concentration of yeast-derived sphingoid base
fraction. Cells were also treated with authentic PHS, DHS or the mixture of PHS and DHS. (D) Transfected cells were cultured with phytoceramide
or dihydroceramide (1 or 10 μM) for 24 h. Luciferase activity was presented as a fold induction relative to that of the control. All results are
shown as means ± S.D. (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, significantly different from the level of vehicle control.
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Figure 6 Effects of sphingolipid administration on cell viability. NIH/3T3 cells were seeded into a 96-well culture plate. (A) C2 ceramide,
phytoceramide and ceramide were dissolved in DMSO, and (B) yeast degradate, PHS and DHS were dissolved in EtOH. These sphingolipids were
added to the cells for 24 h. Cell viability was measured using Cell Counting Kit-8. Cell viability is expressed as a relative value to vehicle control.
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concentration of phytoceramide for 4 h. The luciferase activity was measured and expressed as fold change of control (Ctl). The results represent
the means of triplicate determinations ± S.D. from a representative experiment.
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Page 9 of 11constitutively active PPARb in white adipocytes exhibit
reduced fat mass [31]. Therefore, phytoceramide-
induced activation via PPARb might contribute to the
anti-obesity effect.
It has been reported that PPARb is concerned with
keratinocyte differentiation, and the DES2 protein that
converts dihydroceramide to phytoceramide is expressed
in differentiated keratinocytes. Glucosylceramide in the
extracellular spaces of the epidermis is hydrolyzed to
free ceramide species [32], and these lipids are involved
in skin barrier function. Alkaline ceramidase is highly
expressed in mouse skin and does not digest phytocera-
mide well [33]. Therefore, there is a possibility that phy-
toceramide in epidermis is protected from digestion and
that phytoceramide might regulate epidermis function as
a PPARb ligand.
Conclusion
Our results provide new experimental evidence indicat-
ing that phytoceramide and yeast-derived sphingoid
bases increased transcriptional activities of PPARs. In
addition, phytoceramide elevated PPARa activity in
hepatic cell lines. These findings suggest that phytocera-
mide and sphingoid bases derived from fermented foods
could be used to regulate the expression of PPAR-tar-
geted genes.
Abbreviations
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